X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the license agreement, Gilead will leverage an exclusive global license to develop and commercialize XTX301, Xilio’s tumor-activated IL-12. Currently, it is being evaluated in Phase I clinical trial studies for the treatment of Neoplasms.
Lead Product(s): XTX301
Therapeutic Area: Oncology Product Name: XTX301
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $647.5 million Upfront Cash: $43.5 million
Deal Type: Licensing Agreement March 28, 2024
Details:
XTX301 is an investigational tumor-activated IL-12 designed to potently stimulate anti-tumor immunity. It is under phase 1 clinical development for the treatment of advanced solid tumor.
Lead Product(s): XTX301
Therapeutic Area: Oncology Product Name: XTX301
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
XTX101 is an antibody infusion therapy inhibiting CTLA-4, is being investigated for the treatment of microsatellite stable colorectal cancer in combination with Atezolizumab.
Lead Product(s): XTX101,Atezolizumab
Therapeutic Area: Oncology Product Name: XTX101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
XTX101 is an investigational tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME).
Lead Product(s): XTX101,Pembrolizumab
Therapeutic Area: Oncology Product Name: XTX101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
In preclinical studies, XTX202 exhibited tumor-selective biological activity and anti-tumor activity comparable to aldesleukin, a high-dose IL-2 therapy, at its maximum tolerated dose, while minimizing the severe toxicity observed with aldesleukin.
Lead Product(s): XTX202
Therapeutic Area: Oncology Product Name: XTX202
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
XTX202 is tumor-selective IL-2 product candidate, as a potential treatment for patients with solid tumors. XTX202 is designed to localize activity in the tumor microenvironment (TME).
Lead Product(s): XTX202
Therapeutic Area: Oncology Product Name: XTX202
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
Preclinical studies of XTX101, its tumor-selective anti-CTLA-4 antibody, demonstrating combination potential with anti-PD-1 therapy, as well as enhanced preclinical activity and improved tolerability compared to ipilimumab.
Lead Product(s): XTX101
Therapeutic Area: Oncology Product Name: XTX101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
Proceeds from the financing will be used to advance Xilio’s lead therapeutic candidates, XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4 mAb), into clinical trials.
Lead Product(s): XTX202
Therapeutic Area: Oncology Product Name: XTX202
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Rock Springs Capital
Deal Size: $95.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing February 24, 2021
Details:
The abstract featuring data on XTX201, Xilio’s tumor-selective IL-2, will be shared in a virtual poster viewing session. The abstract featuring data on the tumor-selective aCTLA4 antibody XTX101 will be shared in an oral presentation and in a virtual poster viewing session.
Lead Product(s): XTX201
Therapeutic Area: Oncology Product Name: XTX201
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Proceeds from the financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 and XTX101 through Investigational New Drug enabling studies and into Phase 1 clinical trials.
Lead Product(s): XTX201
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Ventures
Deal Size: $100.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
